Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2018

15.12.2017 | Editorial Commentary

Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’

verfasst von: Ana M. Denis-Bacelar, Sarah J. Chittenden, David P. Dearnaley, Antigoni Divoli, Joe M. O’Sullivan, V. Ralph McCready, Bernadette Johnson, Yong Du, Glenn D. Flux

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

We would like to thank Liepe [1] for his interest in our recent article and giving us the opportunity to further expand upon some additional aspects of the study [2]. …
Literatur
1.
Liepe K. Single high dose versus repeated bone-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2017;44(12):2144–5.
2.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, et al. Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post hoc analysis of the impact of administered activity and dosimetry on survival. Eur J Nucl Med Mol Imaging. 2017;44(4):620–9.
3.
O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, et al. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002;86(11):1715–20.CrossRefPubMedPubMedCentral
4.
O'Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B, et al. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging. 2006;33(9):1055–61.CrossRefPubMed
5.
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91.CrossRefPubMedPubMedCentral
6.
Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(20):3319–24.CrossRefPubMedPubMedCentral
7.
Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436–42.CrossRefPubMedPubMedCentral
8.
Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ, et al. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003;30(8):1114–24.CrossRefPubMed
9.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer. New Engl J Med. 2013;369(3):213–23.CrossRefPubMed
10.
Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52(11):1721–6.CrossRefPubMed
11.
Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–36.CrossRefPubMed
12.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.CrossRefPubMedPubMedCentral
13.
Saluja R, Cheung P, Zukotynski K, Emmenegger U. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Urol Oncol: Semin Orig Investig. 2016;34(5):225–32.CrossRef
Metadaten
Titel
Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’
verfasst von
Ana M. Denis-Bacelar
Sarah J. Chittenden
David P. Dearnaley
Antigoni Divoli
Joe M. O’Sullivan
V. Ralph McCready
Bernadette Johnson
Yong Du
Glenn D. Flux
Publikationsdatum
15.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3902-2

Weitere Artikel der Ausgabe 3/2018

European Journal of Nuclear Medicine and Molecular Imaging 3/2018 Zur Ausgabe

Review Article

Current status of theranostics in prostate cancer

Original Article

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab

Original Article

Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia

Original Article

Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

Image of the Month

Striking lack of visualization of striatum on 18F-FDG brain PET in chorea-acanthocytosis

Editorial Commentary

Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction